404378-60-5

Upstream product

• 10343-13-2 benzyl-2,3,4,6-tetra-O-acetyl-β-D-glucopyranoside 
• 118711-49-2 1,2,4,6-tetra-O-acetyl-3-O-benzyl-L-idopyranoside 
• 27851-28-1 (2R,3R,4S,5R,6R)-2,3,4,5-tetrakis(benzyloxy)-6-((trityloxy)methyl)tetrahydro-2H-pyran 
• 39687-20-2 (2R,3R,4S,5S,6R)-2-(benzyloxy)-6-((trityloxy)methyl)tetrahydro-2H-pyran-3,4,5-triol 
• 27851-29-2 benzyl 2,3,4-tri-O-benzyl-D-glucopyranoside 
• 331233-68-2 Acetic acid (2R,3R,4S,5R,6S)-5-acetoxy-6-acetoxymethyl-4-benzyloxy-2-((2R,3R,4S,5R,6R)-3,4,5,6-tetrakis-benzyloxy-tetrahydro-pyran-2-ylmethoxy)-tetrahydro-pyran-3-yl ester 
• 4304-12-5 (2R,3R,4S,5S,6R)-2-(benzyloxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 
• 256348-52-4 2,4,6-tri-O-acetyl-3-O-benzyl-L-idopyranosyl trichloroacetimidate 

Downstream Products

• 331233-69-3 (4aS,6R,7R,8R,8aR)-8-Benzyloxy-2,2-dimethyl-6-((2R,3R,4S,5R,6R)-3,4,5,6-tetrakis-benzyloxy-tetrahydro-pyran-2-ylmethoxy)-hexahydro-pyrano[3,2-d][1,3]dioxin-7-ol 
• 331233-72-8 5-acetoxy-3-(6-acetoxymethyl-3-azido-4-benzyloxy-5-methoxy-tetrahydro-pyran-2-yloxy)-4-benzyloxy-6-(3,4,5,6-tetrakis-benzyloxy-tetrahydro-pyran-2-ylmethoxy)-tetrahydro-pyran-2-carboxylic acid methyl ester 
• 331233-74-0 3-(3-azido-4-benzyloxy-6-hydroxymethyl-5-methoxy-tetrahydro-pyran-2-yloxy)-4-benzyloxy-5-hydroxy-6-(3,4,5,6-tetrakis-benzyloxy-tetrahydro-pyran-2-ylmethoxy)-tetrahydro-pyran-2-carboxylic acid methyl ester 
• 331233-70-6 Acetic acid (2R,3R,4S,5R,6S)-4-benzyloxy-5-hydroxy-6-hydroxymethyl-2-((2R,3R,4S,5R,6R)-3,4,5,6-tetrakis-benzyloxy-tetrahydro-pyran-2-ylmethoxy)-tetrahydro-pyran-3-yl ester 
• 331233-71-7 (2R,3S,4S,5R,6R)-5-Acetoxy-4-benzyloxy-3-hydroxy-6-((2R,3R,4S,5R,6R)-3,4,5,6-tetrakis-benzyloxy-tetrahydro-pyran-2-ylmethoxy)-tetrahydro-pyran-2-carboxylic acid methyl ester 

Relevant academic research and scientific papers

Synthesis of oligomeric assemblies of a platelet-binding key disaccharide in heparin and their biological activities

Heparin, highly sulfated glycosaminoglycan, binds to platelets. A key disaccharide unit in heparin was previously found to be responsible for the binding, and the frequency of the disaccharide unit was important for the binding potency. A newly developed method based on the reductive amination was effectively applied to prepare structurally defined oligomeric assemblies possessing multiple units of the key disaccharide. From their platelet-binding activities measured by the competitive binding assay, the enhancement of the activity was clearly observed with increasing number of the key disaccharide.